AQR Capital Management Portfolio holdings
AUM
$121B
1-Year Return
23.38%
This Quarter Return
-12.77%
1 Year Return
+23.38%
3 Year Return
+85.44%
5 Year Return
+156.19%
10 Year Return
+370.97%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$649M
Cap. Flow
% of AUM
-1.47%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,361
New
151
Increased
1,005
Reduced
997
Closed
188
Top Buys
| 1 |
Gilead Sciences
GILD
|
+$208M |
| 2 |
CVS Health
CVS
|
+$185M |
| 3 |
Tyson Foods
TSN
|
+$130M |
| 4 |
Exxon Mobil
XOM
|
+$128M |
| 5 |
Citigroup
C
|
+$110M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
+$232M |
| 2 |
Microsoft
MSFT
|
+$191M |
| 3 |
Johnson & Johnson
JNJ
|
+$156M |
| 4 |
Allstate
ALL
|
+$128M |
| 5 |
Walmart
WMT
|
+$120M |
Sector Composition
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.38% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
2051
DELISTED
Immunogen Inc
IMGN
| $137K | ﹤0.01% |
30,392
-209,929
| -87% | -$946K |
|
2052
Vimeo
VMEO
$1.28B
| $135K | ﹤0.01% |
22,587
-74,414
| -77% | -$445K |
|
2053
Alphatec Holdings
ATEC
$2.33B
| $132K | ﹤0.01% |
20,250
-168
| -0.8% | -$1.1K |
|
2054
Solid Biosciences
SLDB
$405M
| $129K | ﹤0.01% |
13,988
-10,541
| -43% | -$97.2K |
|
|
USX
2055
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $129K | ﹤0.01% |
48,319
-60,157
| -55% | -$161K |
|
|
MNTV
2056
DELISTED
Momentive Global Inc. Common Stock
MNTV
| $128K | ﹤0.01% |
14,559
-50,544
| -78% | -$444K |
|
|
EPZM
2057
DELISTED
Epizyme, Inc
EPZM
| $127K | ﹤0.01% |
86,478
-371,192
| -81% | -$545K |
|
|
CONN
2058
DELISTED
Conn's Inc.
CONN
| $126K | ﹤0.01% |
15,745
+5,255
| +50% | +$42.1K |
|
|
SPPI
2059
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $126K | ﹤0.01% |
161,832
+127,252
| +368% | +$99.1K |
|
2060
Acacia Research
ACTG
$310M
| $125K | ﹤0.01% |
+24,773
| New | +$125K |
|
2061
FIGS
FIGS
$1.09B
| $125K | ﹤0.01% |
+13,674
| New | +$125K |
|
2062
Harvard Bioscience
HBIO
$19.7M
| $124K | ﹤0.01% |
34,363
-190,243
| -85% | -$686K |
|
|
TWO
2063
Two Harbors Investment
TWO
$1.06B
| $124K | ﹤0.01% |
6,219
-6,019
| -49% | -$120K |
|
2064
Annexon
ANNX
$258M
| $121K | ﹤0.01% |
32,021
-26,860
| -46% | -$101K |
|
2065
Ambac
AMBC
$415M
| $120K | ﹤0.01% |
10,611
-14,414
| -58% | -$163K |
|
2066
Cardiff Oncology
CRDF
$138M
| $120K | ﹤0.01% |
54,580
-308,703
| -85% | -$679K |
|
2067
Frontline
FRO
$5B
| $120K | ﹤0.01% |
+13,517
| New | +$120K |
|
|
TECX
2068
Tectonic Therapeutic, Inc. Common Stock
TECX
$334M
| $120K | ﹤0.01% |
10,900
-30,598
| -74% | -$337K |
|
|
GHL
2069
DELISTED
Greenhill & Co., Inc.
GHL
| $120K | ﹤0.01% |
+13,001
| New | +$120K |
|
|
LUNA
2070
DELISTED
Luna Innovations Incorporated
LUNA
| $120K | ﹤0.01% |
20,645
+2
| +0% | +$12 |
|
2071
Destination XL Group
DXLG
$68.4M
| $117K | ﹤0.01% |
+34,557
| New | +$117K |
|
2072
8x8 Inc
EGHT
$278M
| $116K | ﹤0.01% |
22,465
-51,083
| -69% | -$264K |
|
2073
Evolus
EOLS
$477M
| $116K | ﹤0.01% |
10,002
-2,143
| -18% | -$24.9K |
|
|
CNSL
2074
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $116K | ﹤0.01% |
16,516
-155,751
| -90% | -$1.09M |
|
2075
Spero Therapeutics
SPRO
$111M
| $115K | ﹤0.01% |
+155,474
| New | +$115K |
|